v3.26.1
Segment (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations

The significant expense categories within net loss are presented on the statements of operations. The research and development expenses have been disaggregated as follows (in thousands):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and engineering expenses

 

$

29,730

 

 

$

36,637

 

 

$

59,213

 

 

$

70,264

 

Clinical expenses

 

 

45,682

 

 

 

30,052

 

 

 

81,246

 

 

 

53,012

 

In-process research and development expenses

 

 

48

 

 

 

2,500

 

 

 

5,048

 

 

 

2,500

 

Total research and development expenses

 

 

75,460

 

 

 

69,189

 

 

 

145,507

 

 

 

125,776

 

General and administrative expenses

 

 

17,934

 

 

 

40,454

 

 

 

35,224

 

 

 

55,250

 

Other segment items#

 

 

(4,985

)

 

 

(4,432

)

 

 

(9,364

)

 

 

(7,572

)

Net loss

 

$

88,409

 

 

$

105,211

 

 

$

171,367

 

 

$

173,454

 

 

# Other segment items is comprised of interest income (expense), net and other income (expense), net.